Lexaria Bioscience (LEXX) Competitors $0.80 -0.03 (-3.73%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$0.78 -0.01 (-1.75%) As of 08/14/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. INCR, OTLK, VNRX, RPTX, IRD, CNTX, FBRX, IZTC, APLT, and INMBShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include InterCure (INCR), Oncobiologics (OTLK), VolitionRx (VNRX), Repare Therapeutics (RPTX), Opus Genetics (IRD), Context Therapeutics (CNTX), Forte Biosciences (FBRX), Invizyne Technologies (IZTC), Applied Therapeutics (APLT), and INmune Bio (INMB). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors InterCure Oncobiologics VolitionRx Repare Therapeutics Opus Genetics Context Therapeutics Forte Biosciences Invizyne Technologies Applied Therapeutics INmune Bio Lexaria Bioscience (NASDAQ:LEXX) and InterCure (NASDAQ:INCR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation. Is LEXX or INCR more profitable? InterCure has a net margin of 0.00% compared to Lexaria Bioscience's net margin of -1,849.19%. InterCure's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Lexaria Bioscience-1,849.19% -157.22% -133.69% InterCure N/A N/A N/A Do insiders & institutionals believe in LEXX or INCR? 13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 26.4% of Lexaria Bioscience shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, LEXX or INCR? Lexaria Bioscience has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, InterCure has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Do analysts rate LEXX or INCR? Lexaria Bioscience presently has a consensus price target of $4.00, indicating a potential upside of 400.63%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Lexaria Bioscience is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, LEXX or INCR? Lexaria Bioscience has higher earnings, but lower revenue than InterCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLexaria Bioscience$460K33.97-$5.80M-$0.67-1.19InterCure$64.55MN/A-$18.32MN/AN/A Does the media favor LEXX or INCR? In the previous week, Lexaria Bioscience had 1 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Lexaria Bioscience and 3 mentions for InterCure. Lexaria Bioscience's average media sentiment score of 0.48 beat InterCure's score of 0.29 indicating that Lexaria Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexaria Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral InterCure 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryLexaria Bioscience beats InterCure on 8 of the 13 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.23M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-1.1920.4930.2925.74Price / Sales33.97356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book1.668.608.826.15Net Income-$5.80M-$54.65M$3.25B$265.06M7 Day Performance-5.44%5.86%3.70%2.60%1 Month Performance-1.90%8.86%5.84%2.83%1 Year Performance-74.63%13.33%29.92%25.58% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience3.7994 of 5 stars$0.80-3.7%$4.00+400.6%-75.1%$16.23M$460K-1.197News CoverageShort Interest ↓INCRInterCure0.5037 of 5 stars$1.50+4.2%N/A-13.1%$65.62M$238.85M0.00350Upcoming EarningsShort Interest ↑OTLKOncobiologics1.7889 of 5 stars$2.01+4.1%$9.60+377.6%-66.9%$64.79MN/A-2.2120News CoverageEarnings ReportGap DownVNRXVolitionRx2.6823 of 5 stars$0.62-2.7%$3.50+461.8%+16.5%$64.78M$1.31M-1.7380News CoverageGap UpRPTXRepare Therapeutics2.8038 of 5 stars$1.52+1.3%$4.50+196.1%-44.7%$64.34M$53.48M-0.50180Earnings ReportIRDOpus Genetics1.863 of 5 stars$1.08+0.9%$7.33+579.0%N/A$63.84M$10.99M-0.5114News CoverageEarnings ReportGap DownCNTXContext Therapeutics3.4858 of 5 stars$0.68-4.2%$5.50+708.8%-71.7%$63.69MN/A-2.197Short Interest ↓Analyst RevisionFBRXForte Biosciences2.633 of 5 stars$9.79+1.9%$61.00+523.1%+69,259.0%$63.27MN/A-0.605News CoverageEarnings ReportIZTCInvizyne TechnologiesN/A$10.08-0.2%N/AN/A$62.99MN/A0.0029Gap DownAPLTApplied Therapeutics4.4085 of 5 stars$0.47+6.6%$6.10+1,197.9%-92.0%$62.39M$460K-1.0930News CoveragePositive NewsEarnings ReportShort Interest ↓Gap DownINMBINmune Bio2.3526 of 5 stars$2.86+11.7%$18.40+543.4%-63.6%$60.38M$10K-1.4810High Trading Volume Related Companies and Tools Related Companies INCR Competitors OTLK Competitors VNRX Competitors RPTX Competitors IRD Competitors CNTX Competitors FBRX Competitors IZTC Competitors APLT Competitors INMB Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access